Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos
Interferon-lambda as effective as alpha but with much better safety profile in hepatitis C
Full speed ahead to curing hepatitis C
Antiretroviral rollout provides a model for efforts to expand hepatitis C treatment and care in resource-limited settings
Studies look at interactions between new hepatitis C drugs and HIV antiretrovirals
GS-7977 plus ribavirin rapidly suppresses HCV but most patients relapse
Telaprevir and boceprevir boost sustained response rates for HIV/HCV coinfected
